Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | F7 | P08709 | 2/20 | 0.39 |
| ▸ | F3 | P13726 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16134490 | 0.87 | HSD17B10 (0.67) | L3MBTL1GAAHSD17B10HRH4TDP1 | |
| SCHEMBL6363091 | 0.83 | HRH4 (0.45) | L3MBTL1GAAHSD17B10HRH4F7 | |
| SCHEMBL16134491 | 0.80 | L3MBTL1 (0.60) | L3MBTL1GAAHSD17B10DAOTDP1 | |
| SCHEMBL16134543 | 0.80 | HSD17B10 (0.77) | L3MBTL1GAAHSD17B10DAOTDP1 | |
| SCHEMBL4506213 | 0.80 | L3MBTL1 (0.60) | L3MBTL1GAAHSD17B10AHRNR4A2 | |
| SCHEMBL17702680 | 0.80 | MAPT (0.50) | L3MBTL1GAAALDH1A1 | |
| SCHEMBL8185211 | 0.79 | GAA (0.57) | L3MBTL1GAAHSD17B10GRIN2DGRIN3B | |
| SCHEMBL16134488 | 0.78 | L3MBTL1 (0.57) | L3MBTL1GAAHSD17B10TDP1NR4A2 | |
| SCHEMBL16134723 | 0.78 | L3MBTL1 (0.57) | L3MBTL1GAAHSD17B10 | |
| SCHEMBL16134489 | 0.78 | L3MBTL1 (0.57) | L3MBTL1GAAHSD17B10TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | claimed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | claimed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | claimed |
| US-20160115136-A1 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2016-04-28 | — | — | US | disclosed |
| WO-2014160405-A1 | COMPOUNDS, COMPOSITIONS COMPRISING SAME, AND METHODS RELATED THERETO | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115136-A1 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO | LPO, NOTUM, FARS2 | L3MBTL1 4609/4885GAA 203/4885HSD17B10 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.